Beyond Air Preannounces Record $2.3M Quarterly Revenue, Up 30% Sequentially
XAIR is trading near its 52-week low of $2.38 (2.9% above the low) on light trading volume (0.2× avg).
Summary
Beyond Air preannounced preliminary unaudited revenue of approximately $2.3 million for the quarter ended September 30, 2026, its highest quarterly figure ever, up 30% sequentially and 27% year-over-year. The growth reflects successful rollout of enhanced commercial execution strategy for the first-generation LungFit PH system. Management reaffirmed CY2026 revenue guidance of $8 million, which excludes revenue from the second-generation LungFit PH system, and CY2027 guidance of $16-$18 million, which includes anticipated revenue from the second-generation system pending FDA approval. The company is pleased with progress of the ongoing PMA supplement process for the second-generation system, and adding transport capability to that system will qualify Beyond Air as a single source nitric oxide provider. The company remains under FDA review for its second-generation LungFit PH and expects demand to increase significantly following approval. This follows the FDA Breakthrough Device Designation for LungFit GO in NTM-PD announced in late August. Full financial results are expected in November 2026.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — The preliminary revenue covers the quarter ended September 30, 2026, and the $8 million CY2026 guidance excludes second-generation LungFit PH revenue.
- Revenue Details — Preliminary revenue is for the quarter ended September 30, 2026, and is unaudited, based on management's preliminary estimates as of October 8, 2026, subject to completion of financial closing procedures and review; actual results may differ materially.
- Growth Driver — Growth reflects successful rollout of enhanced commercial execution strategy for LungFit PH.
- Guidance Exclusions — CY2026 revenue guidance of $8 million excludes revenue from the second-generation LungFit PH system.
- Second-Generation Progress — Company is pleased with progress of ongoing PMA supplement process for second-generation system; adding transport capability will qualify Beyond Air as single source nitric oxide provider.
- Technology and Market — Hospitals see value in cylinder-free nitric oxide technology; LungFit generates NO from ambient air on demand at 1 ppm to 80 ppm, can deliver at or above 80 ppm, and can potentially treat severe acute and chronic refractory lung infections.
All 10 details
- Preliminary revenue is for the quarter ended September 30, 2026.
- Growth reflects successful rollout of enhanced commercial execution strategy for LungFit PH.
- Company is pleased with progress of ongoing PMA supplement process for second-generation system.
- Adding transport capability to second-generation system will qualify Beyond Air as single source nitric oxide provider.
- CY2026 revenue guidance of $8 million excludes revenue from the second-generation LungFit PH system.
- Hospitals see value in Beyond Air's cylinder-free nitric oxide technology, per CEO Robert Goodman.
- LungFit is a cylinder-free, phasic flow generator and delivery system; ventilator-compatible version generates NO from ambient air on demand at 1 ppm to 80 ppm.
- LungFit can deliver NO at concentrations at or above 80 ppm.
- LungFit can potentially treat severe acute lung infections (e.g., COVID-19, bronchiolitis) and chronic, refractory lung infections (e.g., NTM).
- Preliminary revenue is unaudited, based on management's preliminary estimates and information available as of October 8, 2026, subject to completion of financial closing procedures and review of interim financial statements by independent registered public accounting firm, which has not audited, reviewed or performed any procedures; actual results may differ materially.
At the time of this announcement, XAIR was trading at $2.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.5M. The 52-week trading range was $2.38 to $55.60. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.